Inverness Broadens Glucose Monitoring Portfolio Via LXN Acquisition
Inverness Medical Technology's acquisition of privately held LXN Corp., and with it the InCharge GlucoProtein home test, expands the firm's presence in the Type 2 diabetes market.
Inverness Medical Technology's acquisition of privately held LXN Corp., and with it the InCharge GlucoProtein home test, expands the firm's presence in the Type 2 diabetes market.